Estrella Immunopharma Balance Sheet

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Fiscal Year	FY 2025	FY 2024	FY 2024	FY 2023	FY 2023
Period Ending	Sep '25 Sep 30, 2025	Dec '24 Dec 31, 2024	Jun '24 Jun 30, 2024	Jun '23 Jun 30, 2023	Dec '22 Dec 31, 2022
Cash & Equivalents	1.63	4.17	4.17	2.48	0.04
Short-Term Investments	-	-	-	-	9.67
Cash & Short-Term Investments	1.63	4.17	4.17	2.48	9.71
Cash Growth	-60.95%	-	68.02%	-74.47%	-78.73%
Other Receivables	-	-	-	0.27	-
Total Trade Receivables	-	-	-	0.27	-
Other Current Assets	0.4	0.29	0.29	-	0.01
Total Current Assets	2.02	4.45	4.45	2.75	0.05
Other Long-Term Assets	1.5	-	-	0.28	-
Total Assets	3.52	4.45	4.45	3.03	9.72
Accounts Payable	0.01	-	-	9.33	0.33
Accrued Expenses	12.89	0	0	0.02	-
Short-Term Debt	-	-	-	-	0.55
Other Current Liabilities	0.46	0.18	0.18	0.4	0.2
Total Current Liabilities	13.36	0.18	0.18	9.76	1.07
Other Long-Term Liabilities	-	-	-	0.01	1.58
Total Long-Term Liabilities	-	-	-	0.01	1.58
Total Liabilities	13.36	0.18	0.18	9.77	2.65
Preferred Stock	-	-	-	5	-
Common Stock	0	0	0	0	0
Treasury Stock	-0.6	-0.35	-0.35	-	-
Additional Paid-in Capital	27.14	24.12	24.12	0.45	-
Retained Earnings	-36.38	-19.5	-19.5	-12.19	-2.26
Total Common Shareholders' Equity	-9.84	4.27	4.27	-6.74	-2.26
Minority Interest	-	-	-	-	9.33
Shareholders' Equity	-9.84	4.27	4.27	-6.74	7.07
Total Liabilities & Equity	3.52	4.45	4.45	3.03	9.72
Total Debt	0	0	0	0	0.55
Net Cash (Debt)	1.63	4.17	4.17	2.48	9.16
Net Cash Growth	-60.95%	-	68.02%	-72.95%	-79.93%
Net Cash Per Share	0.04	0.15	0.15	8.11	6.46
Book Value	-9.84	4.27	4.27	-6.74	-2.26
Book Value Per Share	-0.27	0.16	0.16	-22.05	-1.59
Tangible Book Value	-9.84	4.27	4.27	-6.74	-2.26
Tangible Book Value Per Share	-0.27	0.16	0.16	-22.05	-1.59

Updated Sep 30, 2025. Data Source: Fiscal.ai. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q